Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase 1/2 4Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 95Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Melanoma 19Triple Negative Breast Neoplasms 14Stomach Neoplasms 13Breast Neoplasms 13Neoplasm Metastasis 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Neoplasms 9Carcinoma 9Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Esophageal Neoplasms 4Cholangiocarcinoma 4Thoracic Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lung Diseases 3

Interventions

Paclitaxel 30Carboplatin 24Cisplatin 11Topotecan 8liposomal doxorubicin 6Hyperthermic Intraperitoneal Chemotherapy 6mirvetuximab soravtansine 5Cyclophosphamide 5Drug Therapy 4Chemotherapy, Adjuvant 4Bevacizumab 4rucaparib 3Peripheral Blood Stem Cell Transplantation 3Neoadjuvant Therapy 3Doxorubicin 3Docetaxel 3CP protocol 3olaparib 2liposomal amphotericin B 2Surgical Procedures, Operative 2Letrozole 2Gemcitabine 2trebananib 1trastuzumab deruxtecan 1phenoxodiol 1pembrolizumab 1oregovomab 1niraparib 1fluzoparib 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Ovarian Epithelial × pembrolizumab × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡